Updates are available Correction dated 2021-09-13
Click to view Correction: https://doi.org/10.1038/s41698-021-00227-7
-
Authors
Conteduca, Vincenza https://orcid.org/0000-0002-6921-714X
Ku, Sheng-Yu
Fernandez, Luisa
Dago-Rodriquez, Angel
Lee, Jerry
Jendrisak, Adam
Slade, Megan
Gilbertson, Cole
Manohar, Jyothi
Sigouros, Michael https://orcid.org/0000-0002-0328-8359
Wang, Yipeng
Dittamore, Ryan
Wenstrup, Rick
Mosquera, Juan Miguel https://orcid.org/0000-0003-4666-6476
Schonhoft, Joseph D.
Beltran, Himisha https://orcid.org/0000-0003-3259-2226
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-17-1-0653)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R27CA241486, P50-CA211024)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 5 January 2021
Accepted: 29 June 2021
First Online: 12 August 2021
Change Date: 13 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41698-021-00227-7
Competing interests
: V.C. has served as consultant/advisory board member for Janssen, Astellas, Merck, AstraZeneca, Bayer; has received speaker honoraria or travel support from Astellas, Janssen, Ipsen, Bayer, and Sanofi. L.F., A.D., A.J., J.L., M.S., Y.W., R.D., C.G., R.W., and J.S. are employed by Epic Sciences Inc. R.D. is employed by Decipher Biosciences. H.B. has served as consultant/advisory board member for Janssen, Pfizer, Sanofi Genzyme, Astellas, Astra Zeneca, Amgen, Merck, Foundation Medicine, Blue Earth Diagnostics, and has received research funding from Janssen Oncology (Inst), AbbVie/Stemcentrx, Eli Lilly (Inst), Millennium Pharmaceuticals (Inst). No potential conflicts of interest were disclosed by the other authors.
